Cargando…
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up
Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney function without increasing the risk for graft rejection...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913628/ https://www.ncbi.nlm.nih.gov/pubmed/20706667 http://dx.doi.org/10.1155/2010/402750 |
_version_ | 1782184681692725248 |
---|---|
author | Frimat, L. Cassuto-Viguier, E. Provôt, F. Rostaing, L. Charpentier, B. Akposso, K. Moal, M. C. Lang, P. Glotz, D. Caillard, S. Ducloux, D. Pouteil-Noble, C. Girardot-Seguin, S. Kessler, M. |
author_facet | Frimat, L. Cassuto-Viguier, E. Provôt, F. Rostaing, L. Charpentier, B. Akposso, K. Moal, M. C. Lang, P. Glotz, D. Caillard, S. Ducloux, D. Pouteil-Noble, C. Girardot-Seguin, S. Kessler, M. |
author_sort | Frimat, L. |
collection | PubMed |
description | Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney function without increasing the risk for graft rejection/loss. To investigate the long-term effect of this regimen, we conducted a follow up study in 70 kidney transplant patients until 5 years after REFERENCE initiation. The improvement of kidney function was confirmed in the MMF group but not in the control group (CsA group). Four graft losses occurred, 2 in each group (graft survival in the MMF group 95.8% and 90.9% in control group). One death occurred in the control group. There was no statistically significant difference in the occurrence of serious adverse events or acute graft rejections. A limitation is the weak proportion of patient still remaining within the control group. On the other hand, REFERENCE focuses on the CsA regimen while opinions about the tacrolimus ones are still debated. In conclusion, CsA reduction in the presence of MMF treatment seems to maintain kidney function and is well tolerated in the long term. |
format | Text |
id | pubmed-2913628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-29136282010-08-12 Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up Frimat, L. Cassuto-Viguier, E. Provôt, F. Rostaing, L. Charpentier, B. Akposso, K. Moal, M. C. Lang, P. Glotz, D. Caillard, S. Ducloux, D. Pouteil-Noble, C. Girardot-Seguin, S. Kessler, M. J Transplant Clinical Study Calcineurin inhibitor (CNI) toxicity contributes to chronic allograft nephropathy (CAN). In the 2-year, randomized, study, we showed that 50% cyclosporin (CsA) reduction in combination with mycophenolate mofetil (MMF) treatment improves kidney function without increasing the risk for graft rejection/loss. To investigate the long-term effect of this regimen, we conducted a follow up study in 70 kidney transplant patients until 5 years after REFERENCE initiation. The improvement of kidney function was confirmed in the MMF group but not in the control group (CsA group). Four graft losses occurred, 2 in each group (graft survival in the MMF group 95.8% and 90.9% in control group). One death occurred in the control group. There was no statistically significant difference in the occurrence of serious adverse events or acute graft rejections. A limitation is the weak proportion of patient still remaining within the control group. On the other hand, REFERENCE focuses on the CsA regimen while opinions about the tacrolimus ones are still debated. In conclusion, CsA reduction in the presence of MMF treatment seems to maintain kidney function and is well tolerated in the long term. Hindawi Publishing Corporation 2010 2010-07-28 /pmc/articles/PMC2913628/ /pubmed/20706667 http://dx.doi.org/10.1155/2010/402750 Text en Copyright © 2010 L. Frimat et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Frimat, L. Cassuto-Viguier, E. Provôt, F. Rostaing, L. Charpentier, B. Akposso, K. Moal, M. C. Lang, P. Glotz, D. Caillard, S. Ducloux, D. Pouteil-Noble, C. Girardot-Seguin, S. Kessler, M. Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
title | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
title_full | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
title_fullStr | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
title_full_unstemmed | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
title_short | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
title_sort | long-term impact of cyclosporin reduction with mmf treatment in chronic allograft dysfunction: referenece study 3-year follow up |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913628/ https://www.ncbi.nlm.nih.gov/pubmed/20706667 http://dx.doi.org/10.1155/2010/402750 |
work_keys_str_mv | AT frimatl longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT cassutoviguiere longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT provotf longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT rostaingl longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT charpentierb longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT akpossok longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT moalmc longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT langp longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT glotzd longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT caillards longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT duclouxd longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT pouteilnoblec longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT girardotseguins longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup AT kesslerm longtermimpactofcyclosporinreductionwithmmftreatmentinchronicallograftdysfunctionreferenecestudy3yearfollowup |